The document discusses Syntaxin Ltd., a biotech company developing recombinant proteins derived from bacterial toxins to treat chronic lung diseases involving mucus hypersecretion. It describes testing of SXN187, a recombinant botulinum neurotoxin protein, on A549 lung cells, finding it reduced intracellular mucin retention in the cells. The goal is to develop a family of medicines using such proteins to inhibit secretion in diseases where it contributes to pathology, like COPD.